Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial

Published:2021-05-27 Issue:11 Volume:11 Page:2812-2827
ISSN:2159-8274
Container-title:Cancer Discovery
language:en
Short-container-title:Cancer Discov

Author:

Carreira Suzanne^ORCID,Porta Nuria,Arce-Gallego Sara,Seed George,Llop-Guevara Alba,Bianchini Diletta,Rescigno Pasquale,Paschalis Alec,Bertan Claudia,Baker Chloe,Goodall Jane,Miranda Susana^ORCID,Riisnaes Ruth,Figueiredo Ines,Ferreira Ana,Pereira Rita,Crespo Mateus,Gurel Bora,Nava Rodrigues Daniel,Pettitt Stephen J.^ORCID,Yuan Wei,Serra Violeta^ORCID,Rekowski Jan^ORCID,Lord Christopher J.^ORCID,Hall Emma^ORCID,Mateo Joaquin,de Bono Johann S.^ORCID

Funder

La Caixa Foundation

Fundacion Cientifica AECC

European Union's Horizon 2020

Instituto de Salud Carlos III

CRIS Cancer Foundation

Cancer Research UK

U.S. Department of Defense

Prostate Cancer Foundation

AstraZeneca

Prostate Cancer UK

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

Cited by 103 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer;Oncogene;2024-09-13

2. A panel‐based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration‐resistant prostate cancer;The Prostate;2024-09-09

3. PARP inhibitor resistance mechanisms and PARP inhibitor derived imaging probes;Expert Review of Anticancer Therapy;2024-09-03

4. Durable benefit from poly(ADP-ribose) polymerase inhibitors in metastatic prostate cancer in routine practice: biomarker associations and implications for optimal clinical next-generation sequencing testing;ESMO Open;2024-09

5. Genetics of prostate cancer: a review of latest evidence;Journal of Medical Genetics;2024-08-13

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3